Amicus Therapeutics, Inc. (FOLD) Short Interest Down 9.2% in October

Amicus Therapeutics, Inc. (NASDAQ:FOLD) saw a large decline in short interest in October. As of October 31st, there was short interest totalling 29,491,417 shares, a decline of 9.2% from the October 13th total of 32,479,058 shares. Approximately 18.5% of the shares of the stock are short sold. Based on an average daily volume of 2,555,483 shares, the short-interest ratio is presently 11.5 days.

In related news, CEO John F. Crowley sold 71,735 shares of the business’s stock in a transaction that occurred on Wednesday, October 18th. The stock was sold at an average price of $14.75, for a total value of $1,058,091.25. Following the transaction, the chief executive officer now directly owns 380,723 shares of the company’s stock, valued at approximately $5,615,664.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO John F. Crowley sold 449,295 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $14.33, for a total value of $6,438,397.35. Following the completion of the transaction, the chief executive officer now directly owns 380,723 shares in the company, valued at $5,455,760.59. The disclosure for this sale can be found here. Over the last three months, insiders sold 628,224 shares of company stock worth $9,024,003. 3.40% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FOLD. UBS Asset Management Americas Inc. increased its position in shares of Amicus Therapeutics by 71.8% during the 1st quarter. UBS Asset Management Americas Inc. now owns 50,674 shares of the biopharmaceutical company’s stock valued at $361,000 after purchasing an additional 21,174 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Amicus Therapeutics by 1.8% during the 1st quarter. Principal Financial Group Inc. now owns 26,883 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 487 shares during the last quarter. Teachers Advisors LLC increased its position in shares of Amicus Therapeutics by 5.4% during the 1st quarter. Teachers Advisors LLC now owns 253,499 shares of the biopharmaceutical company’s stock valued at $1,807,000 after purchasing an additional 12,936 shares during the last quarter. TIAA CREF Investment Management LLC increased its position in shares of Amicus Therapeutics by 6.7% during the 1st quarter. TIAA CREF Investment Management LLC now owns 435,615 shares of the biopharmaceutical company’s stock valued at $3,106,000 after purchasing an additional 27,443 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Amicus Therapeutics by 4.2% during the 1st quarter. Vanguard Group Inc. now owns 8,687,760 shares of the biopharmaceutical company’s stock valued at $61,944,000 after purchasing an additional 353,949 shares during the last quarter.

Amicus Therapeutics (NASDAQ:FOLD) opened at $12.56 on Wednesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. Amicus Therapeutics has a 12-month low of $4.41 and a 12-month high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). The company had revenue of $10.90 million for the quarter, compared to the consensus estimate of $9.02 million. Amicus Therapeutics had a negative net margin of 1,092.37% and a negative return on equity of 63.54%. The business’s revenue for the quarter was up 419.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.33) EPS. equities research analysts anticipate that Amicus Therapeutics will post -1.51 earnings per share for the current year.

FOLD has been the topic of a number of research analyst reports. Leerink Swann reissued an “outperform” rating and issued a $17.00 price target (down from $18.00) on shares of Amicus Therapeutics in a report on Saturday, September 16th. BidaskClub downgraded Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 2nd. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $17.00 price objective on shares of Amicus Therapeutics in a research note on Friday, October 6th. Zacks Investment Research raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Tuesday, October 10th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $16.50 price objective (down previously from $17.50) on shares of Amicus Therapeutics in a research note on Wednesday, September 13th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $17.81.

COPYRIGHT VIOLATION NOTICE: This article was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://ledgergazette.com/2017/11/15/amicus-therapeutics-inc-fold-short-interest-down-9-2-in-october.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply